Good News of PhytoHealth's New Drug, “Oraphine® 60mg Soft Capsule” Approved by the Ministry of Health and Welfare for Marketing

2020 . 07 . 15

Picture/photo of this newspaper

PhytoHealth Corporation (4108) has successfully developed a new application for its drug, Oraphine® 60mg Soft Capsule, which has received approval from the Ministry of Health and Welfare. This drug is an oral formulation designed to alleviate moderate to severe pain.

General Manager Cheng Chien highlighted the multiple advantages of Oraphine®, such as its low potential for addiction and minimal risk of respiratory depression. The active ingredient in Oraphine® is not a controlled substance, which reduces usage restrictions. The oral formulation of the drug significantly enhances convenience and safety, positioning it as a highly competitive product with substantial market potential.

In line with a directive from the US FDA, manufacturers of potent opioid drugs are required to implement a "risk evaluation and mitigation strategy". Vice Chairman Angel Lee noted that Oraphine® 60mg Soft Capsule meets these FDA standards and has secured multiple invention patents in the US, Canada, Japan, China, and Taiwan. Looking ahead, PhytoHealth plans to extend its reach beyond the Taiwan market and tap into the global painkiller market, which is estimated to be worth up to 40 billion US dollars.

Furthermore, PhytoHealth is actively pursuing partnerships in regions such as the US, Japan, and mainland China to secure technology licensing fees and royalties from new drug sales. Several domestic and foreign pharmaceutical companies have already initiated discussions regarding exclusive agency agreements and related distribution contracts.


The original article:《工商時報》懷特新藥傳捷報 懷特痛寶獲衛福部藥證上市

Return